Project description:Primary objectives: To assess the rate of cardiovascular events in patients treated with trifluridine/tipiracil +/- oxaliplatin over a 3-month period.Cardiovascular events are defined as follows:- Acute coronary syndrome without ST segment elevation,- Acute coronary syndrome with ST segment elevation,- Acute myocardial infarction,- Heart failure,- Arrhythmia (atrial fibrillation, flutter, junctional tachycardia, ventricular tachycardia), - Cardiovascular death,- Sudden death of any cause.
Primary endpoints: The rate of cardiovascular events at 3 months
Project description:HuMiChip was used to analyze human oral and gut microbiomes, showing significantly different functional gene profiles between oral and gut microbiome. The results were used to demonstarte the usefulness of applying HuMiChip to human microbiome studies.
Project description:Takotsubo syndrome is a stress-induced cardiomyopathy with symptoms comparable to those of acute coronary syndrome but without coronary obstruction. Initially considered spontaneously reversible, the reversibility of takotsubo was challenged by epidemiological studies showing high morbi-mortality in the long term. Here we explore comprehensively cardiac metabolism, structure and function after a single acute stress. We show that a single pharmacological stress is sufficient to recapitulate the clinical signs of ventricular dysfunction of takotsubo and their apparent reversibility. Interestingly, myocardial glucose metabolic remodeling during the acute phase was also present throughout the late recovery phases. Metabolic stunning where high glucose uptake is derived from glycolysis into alternative non-oxidative pathways such as the hexosamine biosynthetic and polyol pathways parallels with irreversible tissue and vascular remodeling. This study evidences that stress-induced diversion of glucose metabolism is the cause of deleterious structural and functional sequelae in takotsubo hearts.
Project description:We aim to determine blood transcriptome-based molecular signature of acute coronary syndrome (ACS), and to identify novel serum biomarkers for early stage ST-segment-elevation myocardial infarction (STEMI)
